HUP9902327A2 - Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk - Google Patents
Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásukInfo
- Publication number
- HUP9902327A2 HUP9902327A2 HU9902327A HUP9902327A HUP9902327A2 HU P9902327 A2 HUP9902327 A2 HU P9902327A2 HU 9902327 A HU9902327 A HU 9902327A HU P9902327 A HUP9902327 A HU P9902327A HU P9902327 A2 HUP9902327 A2 HU P9902327A2
- Authority
- HU
- Hungary
- Prior art keywords
- antibodies
- humanized antibodies
- human
- compositions containing
- therapeutic use
- Prior art date
Links
- 102100032937 CD40 ligand Human genes 0.000 title abstract 2
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 title abstract 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A találmány tárgyát hűmán gp39-re specifikűs hűmanizált antitestek ésaz antitesteket kódőló DNS-mőlekűlák képezik, tővábbá eljárásők azantitestek előállítására, az antitesteket tartalmazó gyógyászatikészítmények, és találmány szerinti hűmanizált antitestek terápiáshatóanyagként történő alkalmazására. A találmány szerinti antitestekelőnyösen alkalmazhatók aűtőimműn betegségek, példáűl reűmatiődarthritis, szklerózis műltiplex, diabétesz és szisztémás lűpűserythematősűs, valamint nem-aűtőimműn betegségek, példáűl graft-versűshőst betegség kezelésére, és implantátűm kilökődés megelőzésére. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/554,840 US6001358A (en) | 1995-11-07 | 1995-11-07 | Humanized antibodies to human gp39, compositions containing thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9902327A2 true HUP9902327A2 (hu) | 1999-10-28 |
HUP9902327A3 HUP9902327A3 (en) | 2000-12-28 |
Family
ID=24214905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9902327A HUP9902327A3 (en) | 1995-11-07 | 1996-11-07 | Humanized antibodies to human gp39, compositions containing and therapeutic use thereof |
Country Status (11)
Country | Link |
---|---|
US (4) | US6001358A (hu) |
EP (1) | EP0862630B1 (hu) |
JP (1) | JP2000500334A (hu) |
KR (1) | KR100389711B1 (hu) |
AT (1) | ATE364699T1 (hu) |
AU (1) | AU717762B2 (hu) |
DE (1) | DE69637131T2 (hu) |
HU (1) | HUP9902327A3 (hu) |
NO (1) | NO324272B1 (hu) |
NZ (1) | NZ324500A (hu) |
WO (1) | WO1997017446A2 (hu) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
US20030099642A1 (en) * | 1996-04-22 | 2003-05-29 | Michael J. Yellin | Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis |
BR9710264A (pt) * | 1996-07-08 | 1999-08-10 | Univ Columbia | Aplicações terapéuticas da tecnologia do t-bam (cd40l) para tratar de doenças envolvendo as células do músculo liso |
JP2001508450A (ja) * | 1997-01-10 | 2001-06-26 | バイオジェン インコーポレイテッド | 抗cd40l化合物の治療学的投与の方法 |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
CA2291156A1 (en) * | 1997-05-17 | 1998-11-26 | Biogen, Inc. | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
ATE211394T1 (de) * | 1997-06-20 | 2002-01-15 | Tanox Pharma B V | Anti-cd40l immunotoxine zur behandlung von krankheiten |
WO1999000143A1 (en) * | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
EP0937463A1 (en) * | 1998-02-18 | 1999-08-25 | The Procter & Gamble Company | Skin care compositions |
CN100352497C (zh) * | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
KR20020072277A (ko) * | 1999-11-08 | 2002-09-14 | 아이덱 파마슈티칼즈 코포레이션 | 항-cd20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-cd40l 항체를 이용한 b세포 악성종양의치료방법 |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
CN101130078A (zh) * | 2000-04-25 | 2008-02-27 | 拜奥根Idec公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
AU2001261585B2 (en) | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
EP1299128A2 (en) | 2000-06-20 | 2003-04-09 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
SG136804A1 (en) * | 2000-07-12 | 2007-11-29 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
CN100387713C (zh) * | 2000-08-11 | 2008-05-14 | 麒麟医药株式会社 | 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna |
JP2004508420A (ja) * | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | B細胞枯渇抗体/免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
US6768004B2 (en) * | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
EP1414948B1 (en) * | 2001-07-10 | 2009-09-16 | Biogen Idec Inc. | Inhibition of apoptosis process and improvement of cell performance |
NZ533056A (en) | 2001-11-16 | 2007-12-21 | Biogen Idec Inc | Polycistronic expression of antibodies |
EP1466925B1 (en) * | 2001-12-28 | 2009-09-02 | Kyowa Hakko Kirin Co., Ltd. | Antibodies against fibroblast growth factor 23 |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
JP3845735B2 (ja) * | 2002-04-03 | 2006-11-15 | 学校法人慶應義塾 | Cd40lアンタゴニストを有効成分とする天疱瘡治療剤 |
CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
JP4033390B2 (ja) * | 2002-10-30 | 2008-01-16 | 独立行政法人科学技術振興機構 | 不死化ナチュラルキラー細胞株 |
HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
EP1801208A4 (en) | 2004-09-06 | 2009-04-01 | Kirin Pharma Kk | ANTI-A33 ANTIBODIES |
EP1819732A2 (en) | 2004-12-06 | 2007-08-22 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
NZ556286A (en) | 2005-02-07 | 2010-11-26 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
MX2007011407A (es) * | 2005-03-25 | 2007-11-13 | Glycart Biotechnology Ag | Moleculas de union a antigeno dirigidas a proteoglicano de condroitinsulfato de melanoma y con aumento de afinidad de union al receptor fc y de funcion efectora. |
EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
CN101291954B (zh) * | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
AU2012216702B2 (en) * | 2005-08-26 | 2014-12-04 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
TWI390034B (zh) | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
JP5586146B2 (ja) * | 2006-06-06 | 2014-09-10 | 協和発酵キリン株式会社 | ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
JP5209625B2 (ja) | 2006-08-28 | 2013-06-12 | 協和発酵キリン株式会社 | アンタゴニストのヒトlight特異的ヒトモノクローナル抗体 |
JP5081462B2 (ja) * | 2007-02-02 | 2012-11-28 | 富士フイルム株式会社 | トランススプライシング法による融合タンパク質作製方法 |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
PL2801584T3 (pl) * | 2007-12-26 | 2019-12-31 | Biotest Ag | Środki mające za cel CD138 i ich zastosowania |
CN101965366B (zh) * | 2007-12-26 | 2016-04-27 | 生物测试股份公司 | 靶向cd138的免疫缀合物及其应用 |
ES2650267T3 (es) | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
AU2010230346A1 (en) | 2009-03-31 | 2011-07-28 | Roche Glycart Ag | Treatment of cancer with a humanized anti-EGFR IgG1antibody and irinotecan |
EP2426148B1 (en) | 2009-04-27 | 2015-08-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
JP5764127B2 (ja) * | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
EP2473532B1 (en) * | 2009-08-31 | 2017-06-21 | Roche Glycart AG | Affinity-matured humanized anti cea monoclonal antibodies |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
EP2554669B1 (en) | 2010-03-26 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Novel antibody having modification site introduced therein, and antibody fragment |
WO2011152503A1 (ja) | 2010-06-02 | 2011-12-08 | 大日本住友製薬株式会社 | 自己免疫疾患またはアレルギー疾患の治療剤 |
UA115030C2 (uk) | 2011-03-02 | 2017-09-11 | Рош Глікарт Аг | Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа) |
US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
KR20140033152A (ko) | 2011-06-20 | 2014-03-17 | 교와 핫꼬 기린 가부시키가이샤 | 항erbB3 항체 |
LT2766395T (lt) | 2011-10-13 | 2020-03-25 | Bristol-Myers Squibb Company | Antikūno polipeptidai, kaip cd40l antagonistai |
EP2788030B1 (en) | 2011-12-08 | 2018-06-20 | Biotest AG | Uses of immunoconjugates targeting cd138 |
SI2794878T1 (sl) * | 2011-12-22 | 2020-07-31 | F. Hoffmann-La Roche Ag | Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov |
ES2773107T3 (es) | 2012-10-05 | 2020-07-09 | Kyowa Kirin Co Ltd | Composición de proteína heterodimérica |
US9637537B2 (en) | 2012-11-19 | 2017-05-02 | Temasek Life Sciences Laboratories Limited | Monoclonal antibodies targeting neutralizing epitopes on H7 influenza viruses |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
MX2018000548A (es) * | 2015-07-14 | 2018-09-26 | Immunext Inc | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. |
EA201890434A1 (ru) | 2015-08-05 | 2018-10-31 | Янссен Байотек, Инк. | Антитела к cd154 и способы их применения |
CN108699156A (zh) | 2016-03-01 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 具有降低的adcp的奥滨尤妥珠单抗和利妥昔单抗变体 |
PT3231814T (pt) * | 2016-04-14 | 2020-05-06 | Biogenes Gmbh | Um método para produzir células b específicas de antigénio e a sua utilização para a produção de células de hibridoma e anticorpos monoclonais |
AU2018271915A1 (en) | 2017-05-24 | 2019-11-28 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
WO2019013308A1 (ja) | 2017-07-13 | 2019-01-17 | 協和発酵キリン株式会社 | 抗bril抗体及び該抗体を用いたbril融合タンパク質の安定化方法 |
EP3656791A4 (en) | 2017-07-18 | 2021-03-31 | Kyowa Kirin Co., Ltd. | HUMAN ANTI-CCR1 MONOCLONAL ANTIBODY |
US11773180B2 (en) | 2017-11-08 | 2023-10-03 | Kyowa Kirin Co., Ltd. | Bispecific antibody which binds to CD40 and EpCAM |
KR20210027295A (ko) | 2018-06-26 | 2021-03-10 | 쿄와 기린 가부시키가이샤 | 세포 부착 분자3에 결합하는 항체 |
US11965035B2 (en) | 2018-06-26 | 2024-04-23 | Kyowa Kirin Co., Ltd. | Antibody binding to chondroitin sulfate proteoglycan 5 |
WO2020067541A1 (ja) | 2018-09-28 | 2020-04-02 | 協和キリン株式会社 | 抗体組成物 |
SG11202106990PA (en) | 2018-12-28 | 2021-07-29 | Kyowa Kirin Co Ltd | BISPECIFIC ANTIBODY BINDING TO TfR |
WO2020230899A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とfapに結合するバイスペシフィック抗体 |
TW202108625A (zh) | 2019-05-15 | 2021-03-01 | 日商協和麒麟股份有限公司 | 與cd40及gpc3結合之雙專一性抗體 |
EP4039814A4 (en) | 2019-10-02 | 2023-10-11 | Kyushu University, National University Corporation | METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCES, RECOMBINANT CELLS AND METHOD FOR THE PRODUCTION THEREOF |
TW202140561A (zh) | 2020-02-14 | 2021-11-01 | 日商協和麒麟股份有限公司 | 與cd3結合之雙特異性抗體 |
WO2021201236A1 (ja) | 2020-04-01 | 2021-10-07 | 協和キリン株式会社 | 抗体組成物 |
CN111690061B (zh) * | 2020-06-28 | 2022-08-23 | 中国人民解放军东部战区疾病预防控制中心 | 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用 |
CA3229748A1 (en) | 2021-08-26 | 2023-03-02 | Akifumi Kato | Bispecific antibody that binds to cd116 and cd131 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE69233482T2 (de) * | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ES2198025T3 (es) | 1991-10-25 | 2004-01-16 | Immunex Corporation | Anticuerpos contra cd40-l. |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
CN1127351C (zh) * | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性t细胞耐受的方法 |
IL110852A (en) | 1993-09-02 | 1999-05-09 | Dartmouth College | Methods of prolonged suppression of humoral activity |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
AU4352997A (en) | 1996-08-30 | 1998-03-19 | Genzyme Corporation | Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies |
-
1995
- 1995-11-07 US US08/554,840 patent/US6001358A/en not_active Expired - Fee Related
-
1996
- 1996-11-07 AU AU11576/97A patent/AU717762B2/en not_active Ceased
- 1996-11-07 NZ NZ324500A patent/NZ324500A/xx unknown
- 1996-11-07 HU HU9902327A patent/HUP9902327A3/hu unknown
- 1996-11-07 WO PCT/US1996/017875 patent/WO1997017446A2/en active IP Right Grant
- 1996-11-07 EP EP96942732A patent/EP0862630B1/en not_active Expired - Lifetime
- 1996-11-07 AT AT96942732T patent/ATE364699T1/de not_active IP Right Cessation
- 1996-11-07 DE DE69637131T patent/DE69637131T2/de not_active Expired - Fee Related
- 1996-11-07 KR KR10-1998-0703380A patent/KR100389711B1/ko not_active IP Right Cessation
- 1996-11-07 JP JP9518328A patent/JP2000500334A/ja active Pending
-
1998
- 1998-05-06 NO NO19982062A patent/NO324272B1/no unknown
-
1999
- 1999-06-14 US US09/332,595 patent/US6506383B1/en not_active Expired - Fee Related
-
2002
- 2002-06-17 US US10/171,680 patent/US7074406B2/en not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/370,899 patent/US20060147446A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1997017446A2 (en) | 1997-05-15 |
KR100389711B1 (ko) | 2003-10-30 |
NZ324500A (en) | 1999-08-30 |
EP0862630B1 (en) | 2007-06-13 |
DE69637131T2 (de) | 2008-02-07 |
ATE364699T1 (de) | 2007-07-15 |
DE69637131D1 (de) | 2007-07-26 |
US20060147446A1 (en) | 2006-07-06 |
US6001358A (en) | 1999-12-14 |
US7074406B2 (en) | 2006-07-11 |
HUP9902327A3 (en) | 2000-12-28 |
NO982062D0 (no) | 1998-05-06 |
JP2000500334A (ja) | 2000-01-18 |
AU1157697A (en) | 1997-05-29 |
AU717762B2 (en) | 2000-03-30 |
NO324272B1 (no) | 2007-09-17 |
NO982062L (no) | 1998-07-06 |
KR19990067370A (ko) | 1999-08-16 |
EP0862630A2 (en) | 1998-09-09 |
WO1997017446A3 (en) | 1997-09-25 |
US20030175269A1 (en) | 2003-09-18 |
US6506383B1 (en) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9902327A2 (hu) | Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk | |
ATE235917T1 (de) | Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel | |
IL212419A (en) | Use of an isolated human antibody tnfa antibody to create a cure for a disease that is rheumatoid arthritis or autoimmune ovaitis, a pharmacological drug, kit and pre-loaded syringe containing it | |
HUP9902105A2 (hu) | Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása | |
EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
DE69520149T2 (de) | Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen | |
DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
PT735818E (pt) | Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y | |
AU3844297A (en) | Treatment of autoimmune diseases | |
MA28289A1 (fr) | Immunoglobulines | |
HUP0105490A2 (hu) | Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk | |
RU2386639C2 (ru) | Связывающие молекулы, обладающие терапевтической активностью | |
HUP0102479A2 (hu) | Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek | |
HUP9700676A2 (hu) | Rekombináns anti-Fas antitestek és az ezeket kódoló DNS | |
BE900012A (fr) | Nouveau peptide. | |
ATE201601T1 (de) | Pharmazeutische zusammensetzungen enthaltend ein neutralisiertes virus, und verwendung derselben | |
HUP9801759A2 (hu) | Neurodegeneratív betegségek kezelésére alkalmas benzamidok | |
HUP0102853A1 (hu) | Moraxella catarrhalis-ból származó vegyületek | |
FI950962A (fi) | Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä, reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten | |
MY103593A (en) | Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation | |
HUP0004599A2 (hu) | Gonadotropinok expresszáltatása Dictyosteliumban | |
WO2004043397A3 (en) | Compositions and methods for the treatment of rheumatoid arthritis | |
UA66749C2 (en) | Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases | |
FR2706303B1 (fr) | Utilisation de l'Efaroxan et de ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson. | |
MY103584A (en) | 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |